

Two Additional Hospitals Begin Recruiting for Stroke Study

*University of Pittsburgh Medical Center and Chicago's Rush University Medical Center
join in stroke drug trial*

New York, NY, USA – November 14, 2011 – Remedy Pharmaceuticals, Inc. today announced that the University of Pittsburgh Medical Center and Rush University Medical Center have joined the GAMES-PILOT study of RP-1127 and have begun screening patients.

GAMES-PILOT is a multi-center, prospective, open label, Phase 2a trial of RP-1127 in patients with a severe ischemic stroke who are likely to experience clinically significant brain swelling, termed malignant infarction. Malignant infarction is the syndrome of a large stroke causing progressive edema and tissue swelling that compromises arterial inflow to surrounding tissues, culminating in further ischemic damage, enlargement of the infarct, herniation, and death.

The study is already enrolling at the University of Maryland Medical Center and Massachusetts General Hospital. It is anticipated that the information gained in GAMES-PILOT will assist the Company in developing a larger randomized, double-blinded study it has planned for this patient population.

"The addition of Pittsburgh Medical Center and Rush University Medical Center further validates the importance of the GAMES-PILOT study," says Sven Jacobson, Chief Executive Officer of Remedy. "We are excited to have them on board and look forward to their participation in this ground-breaking study."

Detailed information for this study is available at:
<http://clinicaltrials.gov/ct2/show/NCT01268683>

About RP-1127

Remedy's lead drug candidate, RP-1127, is a high affinity, well tolerated inhibitor of NC_{Ca-ATP} channels, which are key upstream mediators of the development of brain swelling (edema) and hemorrhage following ischemic and traumatic injury.

About Remedy Pharmaceuticals

Remedy Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of small molecule drugs for acute central nervous system disorders including stroke, traumatic brain injury, and spinal cord injury.

For more information, email: info@remedypharmaceuticals.com